N4 Pharma
↗Chellaston, Derbyshire, United Kingdom
N4 Pharma is a specialist pre-clinical stage biopharmaceutical company developing Nuvec®, a proprietary silica nanoparticle delivery system designed to enhance cellular delivery and potency of RNA therapeutics, cancer treatments, and vaccines. The company's novel non-viral, non-lipid nanoparticle technology features an irregular surface structure that traps and protects siRNA/RNA/DNA payloads, enabling oral delivery without unwanted immune responses. N4 Pharma's business model focuses on partnering with companies developing novel antigens to use Nuvec® as the delivery vehicle, with the goal of receiving upfront payments, milestone payments, and royalty payments upon market approval. In 2023, the company acquired a controlling interest in Nanogenics, which developed the LipTide® delivery platform for complementary therapeutic applications.
CLASSIFICATION
SIZE & FINANCIALS
Employees:1-50
Revenue:Pre-revenue (TTM: $7-9K)
Founded:2014
Ownership:public
Status:operating
FUNDING
Stage:Pre-IPO/Public
Total Raised:£630K+ (recent placement June 2024)
Investors:Onzima Ventures, Northern Standard Limited, SP Angel
STOCK
Exchange:LSE
Ticker:N4P
Market Cap:£4.37M-£5.51M
PIPELINE
Stage:Preclinical
Lead Drug Stage:Preclinical
Modalities:RNA/siRNA, Gene Delivery, Nanoparticles, Oral Delivery
Active Trials:0
Trial Phases:-
FDA Approvals:0
EMA Approvals:0
CORPORATE STRUCTURE
Subsidiaries:Nanogenics Limited (63.75% ownership as of Sept 2023)
Key Partnerships:SRI International, Medicines Discovery Catapult
COMPETITION
Position:Emerging
Competitors:Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals (Dicerna), Moderna, Jazz Pharmaceuticals, Judo Bio, City Therapeutics, ARO Pharmaceuticals
LEADERSHIP
Key Executives:
Nigel Theobald - Chief Executive Officer and Founder
John Chiplin - Director
David Farrier - Director
Luke Cairns - Director
Dr Fiona McLaughlin - Head of Research and Development
Dr Margaret Courtney - CMC (Chemistry, Manufacturing and Controls) Lead
Scientific Founders:Nigel Theobald
Board Members:Nigel Theobald (CEO, 2.04% shareholder), David Farrier (3.364% shareholder), John Chiplin, Luke Cairns, Edward Wardle (Non-Executive Director, representative of Northern Standard Limited, largest shareholder)
LINKS
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with N4 Pharma. The information on this page was collected and compiled using AI agents from publicly available sources. While we strive for accuracy, this data may be incomplete, outdated, or contain errors. For official information, please visit the company's website directly. If you notice any inaccurate information, please contact us.